Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy

被引:17
|
作者
Kollberg, Gittan [1 ]
Holme, Elisabeth [1 ]
机构
[1] Sahlgrens Univ Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden
关键词
Iron-sulphur cluster deficiency myopathy; ISCU; Antisense oligonucleotide treatment; Morpholino; Phosphorodiamidate morpholino oligonucleotide (PMO); Deep intronic mutation; MUTATION; PROTEIN;
D O I
10.1016/j.nmd.2009.09.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Iron-sulphur cluster deficiency myopathy is caused by a deep intronic mutation in ISCU resulting in inclusion of a cryptic exon in the mature mRNA. ISCU encodes the iron-sulphur cluster assembly protein IscU. Iron-sulphur clusters are essential for most basic redox transformations including the respiratory-chain function. Most patients are homozygous for the mutation with a phenotype characterized by a nonprogressive myopathy with childhood onset of early fatigue, dyspnoea and palpitation on trivial exercise. A more severe phenotype with early onset of a slowly progressive severe muscle weakness, severe exercise intolerance and cardiomyopathy is caused by a missense mutation in compound with the intronic mutation. Treatment of cultured fibroblasts derived from three homozygous patients with an antisense phosphorodiamidate morpholino oligonucleotide for 48 h resulted in 100% restoration of the normal splicing pattern. The restoration was stable and after 21 days the correctly spliced mRNA still was the dominating RNA species. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:833 / 836
页数:4
相关论文
共 50 条
  • [41] Frataxin gene expansion causes aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia
    Rötig, A
    de Lonlay, P
    Chretien, D
    Foury, F
    Koenig, M
    Sidi, D
    Munnich, A
    Rustin, P
    EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 : 36 - 36
  • [42] Antisense oligonucleotide therapeutics: Drug delivery and targeting
    Rojanasakul, YY
    ADVANCED DRUG DELIVERY REVIEWS, 1996, 18 (02) : 115 - 131
  • [43] Antisense oligonucleotide-based therapeutics for cancer
    Dean, NM
    Bennett, CF
    ONCOGENE, 2003, 22 (56) : 9087 - 9096
  • [44] ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY IN THE DEVELOPMENT OF CANCER THERAPEUTICS
    TSENG, BY
    BROWN, KD
    CANCER GENE THERAPY, 1994, 1 (01) : 65 - 71
  • [45] Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases
    Southwell, Amber L.
    Skotte, Niels H.
    Bennett, C. Frank
    Hayden, Michael R.
    TRENDS IN MOLECULAR MEDICINE, 2012, 18 (11) : 634 - 643
  • [46] Nonviral delivery systems for antisense oligonucleotide therapeutics
    Si Huang
    Xin-Yan Hao
    Yong-Jiang Li
    Jun‑Yong Wu
    Da-Xiong Xiang
    Shilin Luo
    Biomaterials Research, 26
  • [47] STUDY OF IRON-SULPHUR SYSTEM IN IRON MONOSULPHIDE (PYRRHOTITE) REGION
    BURGMANN, W
    URBAIN, G
    FROHBERG, MG
    MEMOIRES SCIENTIFIQUES DE LA REVUE DE METALLURGIE, 1968, 65 (7-8): : 567 - &
  • [48] Recent progress in oligonucleotide therapeutics: antisense to aptamers
    Leaman, Douglas W.
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (09) : 997 - 1009
  • [49] Nonviral delivery systems for antisense oligonucleotide therapeutics
    Huang, Si
    Hao, Xin-Yan
    Li, Yong-Jiang
    Wu, Jun-Yong
    Xiang, Da-Xiong
    Luo, Shilin
    BIOMATERIALS RESEARCH, 2022, 26 (01)
  • [50] Antisense oligonucleotide-based therapeutics for cancer
    Nicholas M Dean
    C Frank Bennett
    Oncogene, 2003, 22 : 9087 - 9096